Day One Biopharmaceuticals, Inc. (DAWN) — Financial statements
Income statement, balance sheet, and cash flow for Day One Biopharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 158↑20.6% | 131 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 17↑226.0% | 5↑1278.3% | 0.38↓27.9% | 0.53↑166.8% | 0.20 | |
| Gross Profit | 141↑12.0% | 126↑32967.4% | -0.38↑27.9% | -0.53↓166.8% | -0.20 | |
| Operating Expenses | ||||||
| R&D Expenses | 148↓34.9% | 228↑74.5% | 131↑52.4% | 86↑96.4% | 44 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 121↑4.4% | 115↑53.6% | 75↑23.7% | 61↑109.8% | 29 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 269↓21.7% | 343↑66.8% | 206↑40.5% | 146↑101.8% | 73 | |
| Total Costs & Expenses | 286↓17.9% | 348↑69.1% | 206↑40.3% | 147↑102.0% | 73 | |
| Operating Results | ||||||
| Operating Income | -128↑41.2% | -217↓5.4% | -206↓40.3% | -147↓102.0% | -73 | |
| Depreciation & Amortization | 3↑71.3% | 2↑429.8% | 0.38↓27.9% | 0.53↑166.8% | 0.20 | |
| EBITDA | -106↓22.6% | -86↑54.2% | -189↓33.1% | -142↓95.2% | -73 | |
| EBIT | -109↓23.7% | -88↑53.2% | -189↓32.9% | -142↓95.4% | -73 | |
| Interest & Other Income | ||||||
| Net Interest Income | 18↓6.2% | 20↑14.6% | 17↑262.1% | 5↑118550.0% | 0.00 | |
| Interest Income | 18↓6.2% | 20↑14.6% | 17↑262.1% | 5↑118550.0% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -18↑85.7% | -129↓651.8% | -17↓262.7% | -5↓43081.8% | 0.01 | |
| Other Income / Expenses | 18↓85.7% | 129↑651.8% | 17↑262.7% | 5↑43081.8% | -0.01 | |
| Income Before Tax | -109↓23.7% | -88↑53.2% | -189↓32.9% | -142↓95.4% | -73 | |
| Income Tax Expense | -2↓127.7% | 7 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -107↓12.4% | -95↑49.5% | -189↓32.9% | -142↓95.4% | -73 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -107↓12.4% | -95↑49.5% | -189↓32.9% | -142↓101.3% | -71 | |
| Bottom-Line Net Income | -107↓12.4% | -95↑49.5% | -189↓32.9% | -142↑16.7% | -171 | |
| EPS (Basic) | -1.04↓2.0% | -1.02↑57.0% | -2.37↓17.3% | -2.02↓77.2% | -1.14 | |
| EPS (Diluted) | -1.04↓2.0% | -1.02↑57.0% | -2.37↓17.3% | -2.02↓77.2% | -1.14 | |
| Weighted Average Shares | 103↑10.4% | 94↑17.4% | 80↑21.9% | 65↑5.7% | 62 | |
| Weighted Average Diluted Shares | 103↑10.4% | 94↑17.4% | 80↑21.9% | 65↑5.7% | 62 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.